If you want to buy Montelukast – Singulair Online
Click here to Compare Price of Singulair
|
FDA approval for
Montelukast – Singulair |
Merck & Company Inc. officially declared the approval of their
product Singulair – Montelukast Sodium by the U. S. Food and Drugs
Administration-FDA for the treatment of symptoms of perennial
allergic rhinitis-PAR or indoor allergic reactions in adults and
children of 6 months and above age. The drug is permitted for sale
in the United State in the pill form. Recommended the most
convenient dose of 1 tablet each evening has been proven to helping
relieve the wide range of both indoor and outdoor allergic reaction
symptoms for up to 24 hours.
The drug has been approved for the treatment of the symptoms of
seasonal allergic arthritis-SAR during 2003 and is different from
most oral allergy medications that block histamine, blocking
leukotrienes which are the vital contributor to allergic symptoms.
This medication specifically targets the typical underlying
contributor to allergy symptoms. For treating the symptoms of
allergic rhinitis Singulair is available in 10mg tablet form for
adults and cherry like tasted chewable tablet of 4 or 5mg for
children of 6 months to 5 years of age.
In separate clinical trials of PAR and SAR, this medication has
shown essentially better symptom relief as compared to placebo use.
The efficiency of Singulair – Montelukast Sodium for treating PAR
has been assessed in two randomized, double-blind, placebo managed
studies in the patients ageing between 15 and 82 years of age with
PAR. During one of such specific studies, the drug has displayed
efficacy in progressing the daytime nasal symptoms score, the
preliminary endpoint, evaluated as the average of individual scores
for nasal congestion, runny nose and sneezing conditions.
|
|
